(-0.15%) 5 139.25 points
(-0.12%) 38 513 points
(-0.10%) 17 887 points
(0.40%) $82.96
(2.41%) $2.08
(-1.46%) $2 323.30
(-2.86%) $26.87
(-1.25%) $949.50
(0.16%) $0.934
(0.41%) $11.03
(0.20%) $0.798
(0.05%) $93.35
-0.73% $ 2.72
Live Chart Being Loaded With Signals
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders...
Stats | |
---|---|
Dzisiejszy wolumen | 303 484 |
Średni wolumen | 142 922 |
Kapitalizacja rynkowa | 116.44M |
EPS | $-0.460 ( 2023-11-08 ) |
Last Dividend | $1.512 ( 2023-10-19 ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.563 |
ATR14 | $0.122 (4.49%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-13 | Siegall Clay B | Buy | 20 000 | Stock Option (Right to Buy) |
2023-12-13 | Siegall Clay B | Buy | 0 | |
2023-11-17 | Kulkarni Sandeep Chidambar | Buy | 4 000 | Common Stock |
2023-11-17 | Thiara Parvinder | Buy | 1 000 | Common Stock |
2023-10-27 | Castelein Caley | Buy | 15 800 | Common Stock |
INSIDER POWER |
---|
83.81 |
Last 89 transactions |
Buy: 5 796 448 | Sell: 603 108 |
Wolumen Korelacja
Talaris Therapeutics, Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
MRNS | 0.86 |
NPCE | 0.842 |
ALR | 0.818 |
SMED | 0.817 |
EPZM | 0.815 |
BIS | 0.808 |
THRY | 0.807 |
LTRY | 0.807 |
CNCE | 0.805 |
LVO | 0.802 |
10 Najbardziej negatywne korelacje | |
---|---|
WTBA | -0.867 |
EGAN | -0.854 |
ABST | -0.853 |
CRNT | -0.851 |
BNIXU | -0.85 |
PIXY | -0.834 |
CNDT | -0.832 |
FREQ | -0.823 |
VWE | -0.817 |
UPC | -0.813 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Talaris Therapeutics, Korelacja - Waluta/Towar
Talaris Therapeutics, Finanse
Annual | 2022 |
Przychody: | $0 |
Zysk brutto: | $0 (0.00 %) |
EPS: | $-16.66 |
FY | 2022 |
Przychody: | $0 |
Zysk brutto: | $0 (0.00 %) |
EPS: | $-16.66 |
FY | 2021 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-2.26 |
FY | 2020 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-1.070 |
Financial Reports:
No articles found.
Talaris Therapeutics, Dividends
(Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$1.512 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $1.512 | 2023-10-19 |
Last Dividend | $1.512 | 2023-10-19 |
Next Dividend | $0 | N/A |
Payout Date | 2023-10-20 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $1.512 | -- |
Avg. Dividend % Per Year | 46.23% | -- |
Score | 4.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2023 | $1.512 | 138.70% |
2024 | $0 | 0.00% |
Unable to generate commentary due to missing data.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0 | 1.500 | 0 | 0 | [0 - 0.5] |
returnOnAssetsTTM | -0.382 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -0.364 | 1.500 | -5.16 | -7.74 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 18.64 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 18.14 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 8.28 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00420 | -1.500 | 9.93 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -17.91 | 1.000 | -7.75 | -7.75 | [3 - 30] |
operatingCashFlowPerShareTTM | -12.28 | 2.00 | -4.09 | -8.19 | [0 - 30] |
freeCashFlowPerShareTTM | -12.47 | 2.00 | -6.24 | -10.00 | [0 - 20] |
debtEquityRatioTTM | 0.00444 | -1.500 | 9.98 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0 | 1.000 | -3.33 | -3.33 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0 | 1.000 | -2.00 | -2.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -82.75 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | -1.667 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.202 | 1.000 | -0.121 | 0 | [1 - 100] |
returnOnEquityTTM | -0.364 | 2.50 | -3.32 | -7.74 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -12.47 | 2.00 | -4.16 | -10.00 | [0 - 30] |
dividendYielPercentageTTM | 55.58 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -12.28 | 2.00 | -4.09 | -8.19 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.00392 | 1.500 | -3.36 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0 | 1.000 | -2.50 | 0 | [0.1 - 0.5] |
Total Score | -2.25 |
Talaris Therapeutics,
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej